Broad Institute lands major victory in CRISPR patent fight over UC Berkeley, Nobel winners
Emmanuelle Charpentier and Jennifer Doudna have their Nobel prizes in chemistry for their CRISPR-Cas9 DNA scissors, but the US Patent and Trademark Office made clear late Monday that Harvard-MIT’s Broad Institute and superstar researcher Feng Zhang control the patents involving claims to CRISPR-Cas9 systems for use in eukaryotic (have a nucleus) cells.
The decision was another huge legal blow to the Nobel prize winners, as well as the University of California and University of Vienna, and companies like Intellia Therapeutics and Charpentier-founded CRISPR Therapeutics, which do not have licenses with the Broad Institute. Intellia, which also released some early CRISPR data on Monday, saw its stock price fall by about 9% after hours on Monday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
